 STOCKHOLM , Sept. 8, 2022 PRNewswire -- Medivir AB Nasdaq Stockholm: MVIR, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that an abstract about its lead program fostroxacitabine bralpamide fostrox and the potential efficacy in primary liver cancer has been accepted for presentation at the SITC 37th Annual Meeting, held November 10-12, 2022, in Boston, USA. 